Genvoya vs Triumeq
Side-by-side cost comparison based on Medicare Part D data
Genvoya
Elvitegravir/Cobicistat/Emtricitabine/TAF
Manufactured by Gilead
Triumeq
Dolutegravir/Abacavir/Lamivudine
Manufactured by ViiV Healthcare
Triumeq costs 1% less per claim than Genvoya ($3,580.00 vs $3,619.00). A generic version of Triumeq is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Genvoya | Triumeq |
|---|---|---|
| Avg Cost Per Claim | $3,619.00 | $3,580.00 |
| Total Medicare Spending | $2.3B | $1.9B |
| Total Beneficiaries | 54,000 | 44,000 |
| Total Claims | 648,000 | 524,000 |
| Annual Cost/Patient | $43,426.00 | $42,636.00 |
| Year-over-Year Change | -8.4% | -4.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Gilead | ViiV Healthcare |
| Condition | HIV | HIV |
| Generic Name | Elvitegravir/Cobicistat/Emtricitabine/TAF | Dolutegravir/Abacavir/Lamivudine |
Genvoya vs Triumeq: What the Data Shows
Genvoya (Elvitegravir/Cobicistat/Emtricitabine/TAF) and Triumeq (Dolutegravir/Abacavir/Lamivudine) are both used to treat hiv. Based on Medicare Part D data, Triumeq costs $3,580.00 per claim, which is 1% less than Genvoya at $3,619.00 per claim.
Medicare spent $2.3B on Genvoya and $1.9B on Triumeq. In terms of patient reach, Genvoya serves more beneficiaries (54,000 vs 44,000).
Year-over-year spending changed -8.4% for Genvoya and -4.2% for Triumeq.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Triumeq is cheaper at $3,580.00 per claim, compared to $3,619.00 for Genvoya. That makes Triumeq about 1% less expensive per claim based on Medicare Part D data.
Yes, both Genvoya and Triumeq are used to treat hiv. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Elvitegravir/Cobicistat/Emtricitabine/TAF and generic Dolutegravir/Abacavir/Lamivudine can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $2.3B on Genvoya covering 54,000 beneficiaries, and $1.9B on Triumeq covering 44,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Genvoya and Triumeq on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.